蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响_医学论文.docVIP

蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响_医学论文.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响_医学论文.doc

蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响_医学论文 蛋白酶体抑制剂PS-341对多发性骨髓瘤骨髓间充质干细胞多种细胞因子表达的影响_医学论文 作者:林如峰,陆化,刘澎,沈文怡,张建富,吴雨洁,费小明,李建勇【摘要】 为了探讨蛋白酶体抑制剂PS-341(bortezomib,velcade)对多发性骨髓瘤(MM)患者间充质干细胞(MSC)细胞因子分泌的影响,用含10% FBS的RPMI 1640培养液培养11例MM患者MSC,细胞数达5-10×105时以终浓度50 nmol/L的PS-341作用4小时,用逆转录聚合酶链反应(RT-PCR)检测IL-6、IL-1β、SCF细胞因子表达。结果表明: PS-341作用后MM病人MSC细胞因子的表达有显著下降,IL-6、IL-1β、SCF的表达与对照组比较,其显著性检验结果分别为0.05、0.01、0.05,其中 IL-1β尤为明显;难治复发组与缓解组比较,IL-1β的表达有显著差异,完全缓解(CR)组IL-1β表达受抑制更明显,IL-6、SCF两组间表达无明显差异;PS-341治疗的1例患者MSC在PS-341作用后IL-1β未见表达;IL-1β的表达与否对IL-6、SCF的表达无影响。结论: 蛋白酶体抑制剂PS-341下调MM患者MSC IL-6、IL-1β、SCF细胞因子的表达。 【关键词】 多发性骨髓瘤   Effects of Proteasome Inhibitor PS-341 on the Multiple Cytokine Expressions of Mesenchymal Stem Cells from Bone Marrow in Patients with Multiple Myeloma   Abstract To explore the effects of proteasome inhibitor PS-341 on the cytokine expressions of mesenchymal stem cells (MSC) in patients with multiple myeloma(MM),MSCs of 11 patients were cultured in medium of RPMI 1640 containing 10% FBS. When cells grew to 5×105-1×106,cells were exposed to 50 nmol/L PS-341 for 4 hours,then harvested. The expressions of IL-6,IL-1β and SCF were detected by RT-PCR. The results indicated that after treatment with PS-341 the expressions of IL-6,IL-1β and SCF of MSCs decreased markedly,especially that of IL-1β,compared with control (0.05、0.01、0.05,respectively). There were obviously differences of IL-1β expression between refractory/relapsed group and complete remission(CR)group and IL-1β expression was inhibited more seriously in CR group,whereas there were no significant differences of IL-6 and SCF expression between two groups;IL-1β expression of patients treated with PS-341 was not detected;there were not effects of IL-1β expression on expressions of IL-6 and SCF. It is concluded that proteasome inhibitor PS-341 downregulated the expressions of IL-6,IL-1β and SCF of MSCs in patients with MM .   Key words proteasome inhibitor PS-341;multiple myeloma;mesenchymal stem cell;interlukin-6;inte

文档评论(0)

619731806 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档